NOT MEDICAL ADVICE

5-Amino-1MQ

Estimated Market Price
$134.99 $149.99
Based on verified supplier pricing for research-grade compounds
Small molecule NNMT inhibitor studied in metabolic research for NAD+ salvage pathway regulation, adipocyte differentiation, and cellular energy metabolism.
How it works

Blocks the NNMT enzyme that's overactive in fat tissue, which frees up NAD+ and activates your cells' energy-burning pathways. Promotes fat loss without suppressing appetite.

Performance

Weight Management

What to Expect
Week 1 NNMT inhibition begins; cellular NAD+ levels start rising. Subtle - may notice slightly more energy.
Week 2–3 Enhanced energy metabolism; subtle fat-loss signaling active. Metabolism feels a bit faster; less sluggish after meals.
Week 4–5 Sirtuin pathway fully activated; measurable metabolic shift. Body starting to shift; fat feels less stubborn.
Week 6–8 Peak NNMT inhibition benefits; body composition improving. Visible leaning out; body composition clearly improving.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 50–100 mg oral daily
Administration Oral, Subcutaneous injection
Schedule Once daily, AM with or without food
Protocol Duration 4–8 weeks
Half-Life Not well established
Side Effects & Safety
Tolerability Profile Mild

Generally well tolerated; side effects are mild and transient

Common Side Effects

  • Mild GI discomfortsome users
  • Temporary headachesome users

Less Common

  • Nauseaoccasional
  • Slight energy fluctuationsoccasional
  • Dizzinessoccasional

Rare / Serious

  • Mild liver enzyme elevationrare

Discontinue If

  • Signs of liver stress (dark urine, jaundice, upper-right abdominal pain)
  • Persistent GI distress
  • Severe allergic reaction (rash, swelling)

Contraindications

  • Liver disease or impairment
  • Pregnancy or breastfeeding
  • Concurrent NAD-depleting medications

Data note: Preclinical compound. NNMT inhibition is a novel mechanism — long-term safety data in humans is unavailable.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about 5-Amino-1MQ
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for 5-Amino-1MQ

Also Known As 5-Amino-1-Methylquinolinium, NNMT Inhibitor
Classification Small Molecule · NNMT Inhibitor · Metabolic
Sequence N/A (small molecule, not a peptide)
Molecular Formula C₁₁H₁₂N₂O
Molecular Weight 188.23 Da
CAS Number 42464-95-9
Half-Life Not well established
Origin Synthetic small-molecule NNMT inhibitor
Administration Oral, Subcutaneous injection
Status Research compound - preclinical
Mechanism of Action Blocks the NNMT enzyme that's overactive in fat tissue, which frees up NAD+ and activates your cells' energy-burning pathways. Promotes fat loss without suppressing appetite.
Research Overview 5-Amino-1-methylquinolinium (5-amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that has emerged as a compelling therapeutic target in metabolic disease. Although classified alongside peptides in research catalogs due to its use in similar research contexts, 5-amino-1MQ is technically a modified quinolinium compound rather than a peptide. NNMT catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. This reaction sits at a critical metabolic crossroads because it simultaneously depletes two essential metabolic cofactors - nicotinamide (an NAD+ precursor) and SAM (the universal methyl donor). NNMT expression is markedly upregulated in the white adipose tissue of obese individuals and in multiple cancer types, creating a metabolic environment characterized by reduced NAD+ availability (compromising sirtuin-mediated metabolic regulation) and depleted SAM pools (impairing epigenetic methylation reactions). The foundational work by Neelakantan and colleagues at the University of Texas Medical Branch demonstrated that 5-amino-1MQ treatment in diet-induced obese mice produced significant reductions in body weight and fat mass without affecting food intake - a remarkable finding suggesting that the weight loss resulted from increased energy expenditure and enhanced fat oxidation rather than appetite suppression. The treated animals showed increased NAD+ levels in adipose tissue, enhanced sirtuin activity, reduced adipocyte size, and improved markers of lipid metabolism. Follow-up studies confirmed that NNMT inhibition also improved insulin sensitivity and reduced hepatic steatosis in obese mice. The compound has attracted attention as a potential anti-obesity therapeutic that operates through a novel mechanism entirely distinct from existing weight loss drugs, though it remains in preclinical development stages with no human clinical trials yet initiated.

Citations

Published findings on 5-Amino-1MQ from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.